Kalant H
Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Pain Res Manag. 2001 Summer;6(2):80-91. doi: 10.1155/2001/469629.
To provide an overview of the history and pharmacology of cannabis in relation to current scientific knowledge concerning actual and potential therapeutic uses of cannabis preparations and pure cannabinoids.
The literature on therapeutic uses of cannabis and cannabinoids was assessed with respect to type of study design, quality and variability of data, independent replications by the same or other investigators, magnitude of effects, comparison with other available treatments and reported adverse effects. The results of this review were also compared with those of major international reviews of this topic in the past five years.
Pure tetrahydrocannabinol and several analogues have shown significant therapeutic benefits in the relief of nausea and vomiting, and stimulation of appetite in patients with wasting syndrome. Recent evidence clearly demonstrates analgesic and anti-spasticity effects that will probably prove to be clinically useful. Reduction of intraocular pressure in glaucoma and bronchodilation in asthma are not sufficiently strong, long lasting or reliable to provide a valid basis for therapeutic use. The anticonvulsant effect of cannabidiol is sufficiently promising to warrant further properly designed clinical trials. There is still a major lack of long term pharmacokinetic data and information on drug interactions. For all the present and probable future uses, pure cannabinoids, administered orally, rectally or parenterally, have been shown to be effective, and they are free of the risks of chronic inflammatory disease of the airways and upper respiratory cancer that are associated with the smoking of crude cannabis. Smoking might be justified on compassionate grounds in terminally ill patients who are already accustomed to using cannabis in this manner. Future research will probably yield new synthetic analogues with better separation of therapeutic effects from undesired psychoactivity and other side effects, and with solubility properties that may permit topical administration in the eye, or aerosol inhalation for rapid systemic effect without the risks associated with smoke inhalation.
结合当前有关大麻制剂和纯大麻素实际及潜在治疗用途的科学知识,概述大麻的历史和药理学。
从研究设计类型、数据质量和变异性、同一或其他研究者的独立重复研究、效应大小、与其他可用治疗方法的比较以及报告的不良反应等方面,对有关大麻和大麻素治疗用途的文献进行评估。本综述的结果还与过去五年该主题的主要国际综述结果进行了比较。
纯四氢大麻酚及其几种类似物在缓解恶心和呕吐以及刺激恶病质患者食欲方面已显示出显著的治疗益处。最近的证据清楚地表明其具有镇痛和抗痉挛作用,可能在临床上有用。降低青光眼患者的眼压和哮喘患者的支气管扩张作用不够强大、持久或可靠,无法为治疗用途提供有效的依据。大麻二酚的抗惊厥作用前景良好,值得进一步进行适当设计的临床试验。目前仍然严重缺乏长期药代动力学数据和药物相互作用信息。对于目前和未来可能的所有用途,口服、直肠给药或胃肠外给药的纯大麻素已被证明是有效的,并且它们没有与吸食粗制大麻相关的气道慢性炎症疾病和上呼吸道癌症的风险。对于已经习惯以这种方式使用大麻的晚期患者,出于同情理由,吸烟可能是合理的。未来的研究可能会产生新的合成类似物,其治疗效果与不良精神活性和其他副作用能更好地分离,并且具有溶解性,可能允许眼部局部给药,或通过气雾剂吸入实现快速全身作用,而没有与吸入烟雾相关的风险。